| characteristics | Number (48 patients) | % |
| Age |
|
|
| (Mean ± SD) | 56.8 ± 10.8 |
|
| Median (range) | 57 (29 - 75) |
|
| Sex |
|
|
| Male | 33 | 68.8% |
| Female | 15 | 31.2% |
| ECOG performance status |
|
|
| 0 | 1 | 2.1% |
| 1 | 28 | 58.3% |
| 2 | 19 | 39.6% |
| Pathology |
|
|
| squamous cell carcinoma | 18 | 37.5% |
| adenocarcinoma | 18 | 37.5% |
| Others | 12 | 25% |
| T Stage |
|
|
| 1 | 4 | 8.3% |
| 2 | 16 | 33.3% |
| 3 | 20 | 41.7% |
| 4 | 8 | 16.7% |
| N Stage |
|
|
| 1 | 9 | 18.8% |
| 2 | 19 | 39.6% |
| 3 | 14 | 29.2% |
| 4 | 6 | 12.5% |
| Response to chemotherapy |
|
|
| Partial | 20 | 41.7% |
| Stationary | 28 | 58.3% |
| Number of metastasis |
|
|
| 1 | 3 | 6.3% |
| 2 | 11 | 22.9% |
| 3 | 19 | 39.6% |
| 4 | 10 | 20.8% |
| 5 | 5 | 10.4% |
| EGFR |
|
|
| Negative | 15 | 31.3% |
| Positive | 5 | 10.4% |
| Not applicable | 28 | 58.3% |
| ALK |
|
|
| Negative | 19 | 39.6% |
| Positive | 1 | 2.1% |
| Not applicable | 28 | 58.3% |
| CNS metastasis |
|
|
| Yes | 11 | 22.9% |
| No | 37 | 77.1% |
| Site of metastasis |
|
|
| Single organ | 19 | 39.6% |
| Multiple organ | 29 | 60.4% |